[anecdote] Targets visceral fat; Koniver observes it works better in females than males. — Koniver 00:54–00:56
[anecdote] A type-1 GHRH-mimetic (brand Egrifta), FDA-approved to reduce visceral adiposity; longer-lasting than sermorelin → ~3×/week. — Huberman 00:49–00:51
[anecdote] Stronger GHRH-mimetic than sermorelin; tesamorelin + ipamorelin can drive IGF-1 to ~380–390 (puberty-level); addresses somatopause (GH decline beginning in the 30s). — Bakri 02:05–02:13
[anecdote-bb] Enhancement dosing 1–2 mg SubQ; common injectable combo tesamorelin + ipamorelin (1–3×/day). — Vigorous Steve
Physician protocols
[protocol] ~2 mg (2,000 mcg) per dose, pre-sleep; stacks with ipamorelin + BPC-157 as a one-shot ‘fat-loss’ combination. — Koniver 00:56–00:57
[protocol] Studies use 2 mg once daily; start 1 mg (visceral fat blunts GH; leaner people may need less), max 2 mg. Night dosing, no food ~4 h prior; 5-on/2-off, 3–4 mo on/1 mo off. ~0/dose (3–4× sermorelin). — GH admin guide
Practical notes
[warning] Like GH itself, reduces insulin sensitivity / raises A1C — more so stacked with ipamorelin (‘be lean/healthy enough to take GH’). — Bakri 02:11–02:13
[educational]Insulin-resistance nuance: worsens early, neutralised by ~6 mo only if visceral fat is lost; <8% visceral-fat loss → +8 fasting glucose / +0.2 A1C at 1 yr; 5% developed diabetes vs 1% placebo (label warning). ~50% form antibodies (60% cross-reactive to endogenous GHRH) but efficacy unaffected; wane after stopping. — GH selection guide